Tcg Crossover Gp Ii, Llc Acquires 731 Shares of Surrozen (NASDAQ:SRZN) Stock

Surrozen, Inc. (NASDAQ:SRZN) major shareholder Tcg Crossover Gp Ii, Llc acquired 731 shares of the company’s stock in a transaction that occurred on Monday, February 2nd. The shares were acquired at an average cost of $21.38 per share, with a total value of $15,628.78. Following the purchase, the insider owned 639,507 shares in the company, valued at $13,672,659.66. This represents a 0.11% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Tcg Crossover Gp Ii, Llc also recently made the following trade(s):

• On Tuesday, February 3rd, Tcg Crossover Gp Ii, Llc bought 4,355 shares of Surrozen stock. The stock was acquired at an average cost of $21.94 per share, for a total transaction of $95,548.70.
• On Friday, January 30th, Tcg Crossover Gp Ii, Llc bought 4,271 shares of Surrozen stock. The shares were bought at an average price of $21.39 per share, for a total transaction of $91,356.69.

Surrozen Stock Performance

Shares of SRZN stock traded up $0.98 during trading hours on Tuesday, reaching $23.08. The company had a trading volume of 54,131 shares, compared to its average volume of 146,533. Surrozen, Inc. has a 12-month low of $5.90 and a 12-month high of $24.94. The company has a market capitalization of $197.80 million, a price-to-earnings ratio of -1.03 and a beta of 0.58. The stock has a fifty day moving average of $20.57 and a 200-day moving average of $15.04.

Surrozen (NASDAQ:SRZN) last released its quarterly earnings data on Friday, November 7th. The company reported ($3.61) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.17) by ($2.44). Surrozen had a negative return on equity of 4,055.04% and a negative net margin of 2,909.10%.The company had revenue of $0.98 million for the quarter. On average, analysts forecast that Surrozen, Inc. will post -8.49 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in SRZN. Stempoint Capital LP lifted its stake in Surrozen by 185.1% during the 2nd quarter. Stempoint Capital LP now owns 686,539 shares of the company’s stock worth $6,138,000 after acquiring an additional 445,713 shares in the last quarter. Stonepine Capital Management LLC lifted its position in shares of Surrozen by 7.1% during the second quarter. Stonepine Capital Management LLC now owns 306,029 shares of the company’s stock worth $2,736,000 after purchasing an additional 20,247 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Surrozen by 21.7% during the third quarter. Vanguard Group Inc. now owns 266,418 shares of the company’s stock worth $3,433,000 after purchasing an additional 47,468 shares in the last quarter. Acuta Capital Partners LLC boosted its stake in shares of Surrozen by 5.0% in the third quarter. Acuta Capital Partners LLC now owns 178,415 shares of the company’s stock valued at $2,299,000 after purchasing an additional 8,415 shares during the period. Finally, Braidwell LP acquired a new position in shares of Surrozen in the second quarter valued at approximately $1,252,000. 66.57% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. Lifesci Capital raised shares of Surrozen to a “strong-buy” rating in a research note on Thursday, November 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Surrozen in a research note on Thursday, January 22nd. Finally, Wall Street Zen upgraded Surrozen to a “sell” rating in a research report on Friday, November 28th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Surrozen presently has a consensus rating of “Moderate Buy” and a consensus price target of $32.00.

About Surrozen

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.